2025
conference-abstract
OpenAlex
Varun Iyengar, Jomel Meeko Manzano, Lu Chen, Jessica Chicola et autres
Abstract Introduction Pola-RCHP is a new standard of care (SOC) in the frontline (1L) treatment of DLBCL. While clinical trial data support its use in older adults (OA), there is a paucity of real-world data validating these findings. The impact of frailty …
us, Afrique du Sud
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Nikita Dave, Alexandra D. Dreyfuss, Alison J. Moskowitz, Joachim Yahalom et autres
Abstract Intro Early-stage classical Hodgkin lymphoma (cHL) is a highly curable malignancy. Traditionally, patients (pts) have been treated with combined modality therapy (CMT) using A(B)VD +/- consolidative radiotherapy (RT). Given potential toxicities of RT, trials have investigated excluding RT but have failed …
us
(code pays fourni par la source)
2025
article
OpenAlex
Jessica Chicola, Jomel Meeko Manzano, Lu Chen, Varun Iyengar et autres
2025
article
OpenAlex
Jessica Chicola, Jomel Meeko Manzano, Lu Chen, Varun Iyengar et autres
Accès ouvert
2025
article
OpenAlex
Liangyi Chen, Sophie A Buller, Venkatesh Iyengar, Gloria Isabel Carvajal Peláez et autres
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Jesús G. Berdeja, Min Yang, Noopur S Raje, Edward N. Libby et autres
us
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Oliver Van Oekelen, Nicole Birrer, William C. Wesson, Vincent L. Galate et autres
As the survival of patients with newly diagnosed multiple myeloma (MM) has continued to improve, there is a need for prolonged follow-up to demonstrate a progression-free or overall survival benefit [ 1 ]. A valid surrogate endpoint could reduce cost and duration …
us
(code pays fourni par la source)
Accès ouvert
2022
conference-abstract
OpenAlex
Oliver Van Oekelen, Nicole Birrer, William C. Wesson, Vince Galate et autres
2016
article
OpenAlex
Jens G. Lohr, Sora Kim, Joshua Gould, Birgit Knoechel et autres
Abstract Continuous genomic evolution has been a major limitation to curative treatment of multiple myeloma (MM). Frequent monitoring of the genetic heterogeneity in MM from blood, rather than serial bone marrow (BM) biopsies, would therefore be desirable. We hypothesized that genomic characterization …
us
(code pays fourni par la source)
Accès ouvert
2016
article
OpenAlex
Jens G. Lohr, Sora Kim, Joshua Gould, Birgit Knoechel et autres
Multiple myeloma (MM) remains an incurable disease, with a treatment-refractory state eventually developing in all patients. Constant clonal evolution and genetic heterogeneity of MM are a likely explanation for the emergence of drug-resistant disease. Monitoring of MM genomic evolution on therapy by …
us
(code pays fourni par la source)
2016
article
OpenAlex
Andrew Jenho Yee, William Bensinger, Jeffrey G. Supko, Peter Michael Voorhees et autres
us
(code pays fourni par la source)
Accès ouvert
2016
article
OpenAlex
Ryan David Nipp, Hang Lee, Elizabeth Ellen Powell, Nicole Birrer et autres
INTRODUCTION: Cancer clinical trial (CT) participation rates are low and financial barriers likely play a role. We implemented a cancer care equity program (CCEP) to address financial burden associated with trial participation. We sought to examine the impact of the CCEP on …
us
(code pays fourni par la source)